A prospective randomized study of sulphonylureas therapeutic interchange in patients with type 2 diabetes mellitus;Estudio prospectivo y aleatorizado de intercambio terapéutico de sulfonilureas en pacientes con diabetes mellitus tipo 2

Farmacia Hospitalaria

Volumn 28, Issue 6, 2004, Pages 426-432

  Crespí Monjo, Mar ^a   Delgado Sanchez O ^a   Ventayol Bosch, P ^a   Lafuente Flo A ^b   Pinteno Blanco M ^a   Escriva Torralva A ^a   Puigventos Latorre F ^a   Martinez Lopez I ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Glibenclamide; Gliclazide; Sulphonylureas; Therapeutic interchange; Type 2 diabetes mellitus

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOMES RESEARCH; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLICLAZIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 13444306677     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Part 1: Report of a WHO Consultation: Diagnosis and Classification of Diabetes Mellitus. Ginebra: World Health Organization, 1999.
2. World Health Organization: Prevalence of Diabetes Worldwide. http://www.who.int/diabetes/facts/world_figures.en.
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care 1998; 21: 1414-31.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylreas or insulin compared with conventional treatment andr risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
6. Nathan DM. Initial management of glycemia in Type 2 Diabetes Mellitus. N Engl J Med 2002; 347: 1342-9.
7. Inzucchi SE. Oral Antihyperglycemic Therapy for Type 2 Diabetes. Scientific Review. JAMA 2002; 287 (3): 360-72.
8. Herrera Pombo JL. Tratamiento de la diabetes mellitus. Sulfonilureas. Medicine 1997; 7 (64): 2984-90.
9. a ed. Madrid: SCM, 2002. p. 101-11.
10. Document of care for older people with diabetes, Clinical Guidelines, British National Formulary. Postgrad Med J 1996; 72: 334-8.
11. Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, et al. 1998 clinical practice guidelines for the managment of diabetes in Canada. CMAJ. JAMC 1998; 159 (Supl. 8).
12. Harrover ADB. Comparative Tolerability of Sulphonylureas in Diabetes Mellitus. Drug Safety 2000; 4: 313-20.
13. Segal R, Grines LL, Pathak DS. Opinions of pharmacy, medicine, and pharmaceutical industry leaders about hypothetical therapeutic-interchange legislation. Am J Hosp Pharm 1988; 45: 570-7.
14. Carmona G, Ortega P, Torres FI, Guevara E, Valle I, López E. Intervención farmacéutica en la prescripción de medicamentos. Farm Hosp 1999; 23 (Esp Congr): 10.
15. Ferriols R. Evaluation of pharmacist intervention in Medication Related Problems (MRP). Spring Conference on Clinical Pharmacy (Reykjavik Iceland 10-13 May 2000).
16. Aznarte P, Díaz MS, Martínez de Guzmán M, Fernández E, Nájera M. Evaluación de la intervención farmacéutica en un sistema de distribución de medicamentos en dosis unitarias. Farm Hosp 1999; 23 (Esp Congr): 9.
17. Clopés A, Castro I, Sala ML, Farré R, Ramos J, Gámez M. Evaluación del impacto de las intervenciones del farmacéutico clínico en la atención al paciente. Farm Hosp 1999; 23 (Esp Congr): 5.
18. Delgado O, Puigventós F, Llodrá V, Comas F, Cervera M, Sánchez A. Programa para la sustitución de equivalentes terapéuticos en el medio hospitalario. Rev Clín Esp 2000; 200: 261-70.
19. Wall DS, Abel SR. Therapeutic-interchange algorithm for multiple drug classes. Am J Health-Syst Pharm 1996; 53: 1295-6.
20. American College Of Clinical Pharmacy. Guidelines for therapeutic interchange. Pharmacotherapy 1993; 13 (3): 252-6.
21. a ed. Palma de Mallorca: Comisión de Farmacia y Terapéutica del Hospital Universitario Son Dureta, 2001.
22. Ventayol P, Delgado O, Cervera M, Sánchez A, Escrivá A, Ginés J, et al. Intercambio terapéutico de IECA: valoración de la sustitución. Farm Hosp 2000; 24 (Supl.): 28-9.
23. Martínez-López I, Ventayol P, Cervera M, Escrivá A, Puigventós F, Delgado O. Inhibidores de la enzima convertidora de angiotensina (IECA) ¿se pueden sustituir? Farm Hosp 2001; 25 (Supl): 101.
24. Ventayol P, Puigventós F, Delgado O, Martínez I, Maroto A, Comas F, et al. Programas de intercambio terapéutico en el hospital: la evidencia en favor del paciente. El farmacéutico de hospitales; 2002: 428.
25. Graal MB, Wolffenbuttel BHR. The use of Sulphonylureas in the elderly. Drugs and Aging 1999; 15 (6): 471-81.
26. Raptis A, Tountas N, Yalouris A, Hadjikari D, Zaharis A, Miras K, et al. Comparative Study of the Therapeutic Effects of Glibenclamide or the fixed combination of Glibenclamide-Phenformin with those of Gliclazide or Chlorpropamide. Acta Diabetol Lat 1990; 27 (1): 11-22.
27. Harrower ADB. Comparison of diabetic control in type 2 (non insulin dependent) diabetic patients treated with different sulphonylureas. Curr Med Res Opin 1985; 9: 676-80.
28. Tessier D, Dawxon K, Tetrault J, Bravo G, Meneilly GS. Comparison of glibenclamide vs gliclazide in the treatment of NIDDM in subjects older than 65. Diab Med 1994; 11: 944-80.
29. Harrower ADB. Effective of Gliclazide in comparison with other sulphonylureas in the treatment of DMNID. Diabetes Research and Clinical Practice 1991; 14: S65-8.
30. Crespí M, Escrivá A, Delgado Sánchez O, Sans JG, Martínez López I, Ventayol P, et al. Estudio prospectivo y aleatorizado de intercambio terapéutico de sulfonilureas en pacientes con diabetes mellitus no insulino dependiente. XLVII Congreso Nacional de la Sociedad Española de Farmacia Hospitalaria. Barcelona, septiembre 2002.
31. Gregorio F, Ambrosi F, Filiponi P. Therapeutic concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone with different leves of glucose: in vitro effects over funtion of alfa and beta cells. Diabetes Res Clin Pract 1992; 18: 197-206.
32. Pearson JG, Antal EJ, Raehl CC, Gorsch HK, Craig WA, Albert KS. Pharmacokinetic disposition of glyburide in patients with varying renal function. Clin Pharmacol Ther 1986; 39: 318-24.
33. Rydberg T, Jonsson A, Roder M, Melander A. Hypoglycaemic activity of glyburide (glibenclamide) metabolites in humans. Diabet Car 1994; 17: 1026-30.
34. Herrera Pombo JL. Tratamiento de la Diabetes Tipo 2. Fármacos Insulinosecretores. En: Actualizaciones y protocolos clínicos: Diabetes Mellitus tipo II. Madrid: Doyma, 2000. p. 73-81.
35. Mailhot J. Efficacy and safety of gliclazide in NIDDM; Canadian multicentric study. Clin Ter 1993; 15: 1060-8.
36. Baba S, Nakagawa S, Takebe K, Goto Y, Maezewa H, Takeda R, et al. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes. Tohoku J Exp Med 1983; 14 (Supl.): 693-706.